$35.66
+1.39%
N/A+$0.49
헬스케어
생명공학
NASDAQ
활발히 거래 중
Pharvaris N.V.는 후기 단계의 바이오제약 회사로, 유전성 혈관부종(HAE) 및 기타 브래디키닌 매개 질환을 포함한 충족되지 않은 의료 수요가 있는 희귀 질환 치료제의 ...
Pharvaris N.V.는 후기 단계의 바이오제약 회사로, 유전성 혈관부종(HAE) 및 기타 브래디키닌 매개 질환을 포함한 충족되지 않은 의료 수요가 있는 희귀 질환 치료제의 ...
Deucrictibant immediate-release capsules are an investigational small-molecule therapy targeting the bradykinin B2 receptor. It is formulated for rapid onset of activity to address the acute symptoms of hereditary angioedema (HAE) and has recently reached the milestone of FDA acceptance for a New Drug Application (NDA).
가격대: N/A (Clinical-stage, not yet commercialized)
페인 포인트: Replaces the need for invasive injectable therapies; addresses the physical burden and unpredictable nature of HAE attacks; provides a convenient, portable oral option for patients.
솔루션: Provides rapid symptom relief, reduces attack duration, and offers a patient-friendly oral alternative to traditional HAE treatments.
대상 사용자: Patients diagnosed with hereditary angioedema (HAE) and acquired angioedema (AAE) seeking on-demand treatment options.
Deucrictibant extended-release tablets are designed to provide sustained absorption and prophylactic efficacy. This formulation aims to offer a convenient, daily oral dosing regimen to prevent the occurrence of HAE attacks, potentially shifting the standard of care away from injectable prophylactic agents.
가격대: N/A (Clinical-stage, not yet commercialized)
페인 포인트: Reduces the reliance on frequent preventative injections; minimizes the psychological and physical strain of managing a chronic, rare disease.
솔루션: Provides consistent, reliable prevention of angioedema attacks with the convenience of an oral dosage form.
대상 사용자: Patients requiring long-term, daily prophylaxis for hereditary angioedema (HAE) to manage disease recurrence.